Protalix BioTherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1997
Cash & Equivalents	23.63	17.11	38.99	18.27	17.79	37.81	51.16	63.28	76.37	54.77	Upgrade
Short-Term Investments	20.93	5.07	0	20.28	0	0	0	0	0	0	Upgrade
Cash & Cash Equivalents	44.56	22.18	38.99	38.55	17.79	37.81	51.16	63.28	76.37	54.77	Upgrade
Cash Growth	100.90%	-43.11%	1.14%	116.64%	-52.94%	-26.10%	-19.15%	-17.14%	39.45%	-36.61%	Upgrade
Receivables	5.27	4.59	3.44	2	4.7	4.73	1.72	0.69	0	0	Upgrade
Inventory	19.05	16.8	17.95	13.08	8.16	8.57	7.83	5.25	5.77	3.45	Upgrade
Other Current Assets	1.06	1.31	1.29	2.1	1.83	1.88	1.93	2.65	3.74	7.3	Upgrade
Total Current Assets	69.93	44.88	61.67	55.72	32.48	52.98	62.65	71.87	85.88	65.52	Upgrade
Property, Plant & Equipment	10.88	9.64	9.92	10.41	10.95	6.39	7.68	8.7	9.74	11.28	Upgrade
Other Long-Term Assets	3.62	1.27	2.08	1.8	1.96	1.76	1.89	1.68	1.63	1.56	Upgrade
Total Long-Term Assets	14.5	10.91	12	12.21	12.91	8.15	9.56	10.38	11.37	12.84	Upgrade
Total Assets	84.43	55.79	73.67	67.93	45.39	61.13	72.21	82.25	97.25	78.36	Upgrade
Accounts Payable	23.87	18.13	23.42	21.15	18.4	15.49	16.83	11.5	9.16	10.64	Upgrade
Deferred Revenue	0	0	0	0	0	0	0	0.84	1.25	0.89	Upgrade
Current Debt	21.66	1.12	1.21	59.93	5.44	0	5.92	53.87	0	0	Upgrade
Other Current Liabilities	0	13.18	8.55	5.39	16.34	9.87	0	0	0.82	52.83	Upgrade
Total Current Liabilities	45.53	32.43	33.18	86.47	40.18	25.35	22.75	66.21	11.24	64.35	Upgrade
Long-Term Debt	4.62	32.36	32.26	4.47	55.49	47.97	46.27	19.34	72.1	67.35	Upgrade
Other Long-Term Liabilities	0.71	1.64	14.26	4.03	20.05	40.69	32.65	6.65	3.05	2.25	Upgrade
Total Long-Term Liabilities	5.34	34	46.53	8.5	75.54	88.66	78.92	25.99	75.15	69.6	Upgrade
Total Liabilities	50.87	66.43	79.7	94.97	115.71	114.01	101.67	92.2	86.38	133.96	Upgrade
Total Debt	26.28	33.47	33.47	64.4	60.93	47.97	52.19	73.22	72.1	67.35	Upgrade
Debt Growth	-21.49%	0.01%	-48.03%	5.70%	27.02%	-8.09%	-28.72%	1.55%	7.05%	0.45%	Upgrade
Retained Earnings	-381.55	-389.86	-374.93	-347.35	-340.83	-322.55	-296.1	-212.66	-183.29	-241.33	Upgrade
Shareholders' Equity	33.57	-10.64	-6.04	-27.04	-70.32	-52.88	-29.46	-9.96	10.87	-55.6	Upgrade
Net Cash / Debt	18.28	-11.29	5.52	-25.86	-43.13	-10.16	-1.03	-9.93	4.28	-12.58	Upgrade
Net Cash Per Share	0.22	-0.23	0.12	-0.89	-2.91	-0.69	-0.08	-0.98	0.45	-1.35	Upgrade
Working Capital	24.4	12.45	28.49	-30.75	-7.7	27.63	39.9	5.66	74.65	1.17	Upgrade
Book Value Per Share	0.50	-0.22	-0.14	-0.93	-4.74	-3.59	-2.25	-0.98	1.15	-5.99	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).